|

Selinexor 40 mg Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Duke University1

Indications

  • Multiple Myeloma, Refractory1
  • Multiple Myeloma in Relapse1
  • Cancer1

Durham, North Carolina1 trial

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Duke University Health System

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.